Multiresistant organisms: bacteria and beyond

Abstract

Purpose of reviewInfections with multiresistant organisms are an emerging problem, cause early mortality post lung transplantation and are sometimes associated with graft dysfunction. Frequently they raise questions about the selection of lung transplant candidates and therapeutic management post lung transplantation. There are no guidelines and management must be individualized. This review summarizes the available therapeutic options in cases of multidrug-resistant (MDR) organisms and outcomes after lung transplant.Recent findingsImprovements in diagnosis, new and more effective drugs and the experience gained in the management of these infections in lung transplantation, lead to a more optimistic horizon than that found a decade ago.SummaryUpdate on the management of Burkholderia cepacia complex, Mycobacterium abscessus complex, Aspergillus spp., Scedosporium spp. and Lomentospora prolificans infections. This review clarifies current posttransplant outcomes and adds a little hope in these scenarios.

Reduced Antibiotic Resistance in the Rhizosphere of Lupinus albus in Mercury-Contaminated Soil Mediated by the Addition of PGPB

“…These ARGs can be transmitted to bacteria with clinical relevance, and new multiresistant bacteria may appear [ 22 , 23 , 24 , 25 ] threatening the “One Health” approach. For this reason, the World Health Organization (WHO, Geneva, Switzerland) has declared ARGs to be a new pollutant due to their emerging prevalence and wide distribution.…”